Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) leg type is an aggressive type of CBCL, characterized by skin lesions mainly on the legs and a predominance of diffuse sheets of centroblasts and immunoblasts. Given the poor prognosis, old age at onset, frequent relapses, and extracutaneous spread, PCDLBCL, leg type is a distinct type of cutaneous lyphoma. Here the clinicopathology of extranodal lymphomas will be discussed.
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Clinics and pathology
Disease PCDLBCL, leg type is composed exclusively of large transformed B-cells, most commonly arising in the leg. PCDLBCL, leg type was first reported as a subgroup of PCFCL in 1987 based on its particular histological feature and more aggressive behavior. In 1996, the term "primary cutaneous large B-cell lymphoma of the leg" was proposed, which was used to classify it as a distinctive subgroup in the EORTC classification. In the last WHO-EORTC classification, this entity was finally defined PCDLBCL, leg type to reflect the predominant but not exclusive anatomic location of the lesions (Swerdlow, et al, 2008 . Selva, et al, 2017 .
Phenotype/cell stem origin
Tumor cells express B-cell markers (CD20, CD79a, and PAX5). Cytoplasmic IgM expression seems to be a sensitive marker of PCDLBCL, leg type. BCL-2, MUM1/IRF4, and FOX-P1 are strongly expressed regardless of the location of the skin lesions. A study suggests that cell-of origin is germinal center experienced and superantigen driven selected B-cell, in a stage between germinal center B-cell and plasma cell (Swerdlow, et al , 2008 . Selva, et al, 2017 .
Epidemiology
PCDLBCL, LT represents 5%-10% of all PCBCLs commonly presenting in elderly females (male:female 1:3-4), with a peak incidence in the seventh decade of life (Swerdlow, et al , 2008 . Selva, et al, 2017 .
Clinics
Patients present solitary or multiple, rapidly growing, red to bluish-red firm tumors on one or both legs, usually below the knee. In 10%-15% of cases, the lesions are localized at other sites such as the trunk, head-neck, and upper arms. Multiple lesions may be disseminated or aggregated. Extracutaneous sites are often disseminated, most commonly in lymph nodes, bone marrow, and nervous system (Swerdlow, et al , 2008 . Selva, et al, 2017 .
Pathology
Histologically, there is a diffuse and dense infiltrate throughout the dermis that often involves the subcutis but is separated from the epidermis by a Grenz zone. The infiltrate mainly consists of confluent sheets of large B-cells with roundish nuclei, prominent nucleoli, and open chromatin resembling centroblasts and immunoblasts. Anaplastic cells are occasionally seen. Mitotic figures are frequently observed. T-cells are rare. PCDLBCL, leg type is usually characterized by a high proliferation rate (>70%) and BCL-6, CD5, CD10, CD30, CD138, and cyclin D1 negativity. 
Treatment
PCDLBCL, leg type is often managed as a systemic lymphoma depending on its staging and location, number of skin lesions, and general status of the patient. Immunochemotherapy with R-CHOP with or without involved-field radiotherapy as the firstline therapy for single, localized, or generalized lesions is recommended. The use of local radiotherapy or rituximab as a single agent can be considered in particular cases. In relapsed cases, the use of protocols for relapsed systemic DLBCLs is recommended (Swerdlow, et al ,2008 . Selva, et al, 2017 . Wilcox, 2016 . Targeting of tumor cells and myeloid-derived suppressor cells using anti-PD-1/ anti -PD-L1 or anti-CD33 antibodies might be a worthwhile new approach to treat PCDLBCL, leg type (Mitteldorf, et al. 2017 ).
Prognosis
The prognosis of PCDLBCL, LT is poor and characterized by frequent relapses and extracutaneous spreading. The 5-year survival rate is 40%-55%. A location on the leg and multiple skin lesions are negative prognostic factors. Factors that have been reported to be linked to a worse prognosis are the high expression of MUM1 and FOX-P1, and deletion of the CDKN2A locus on chromosome 9p21 (Swerdlow, et al, 2008 . Selva, et al, 2017 .
Cytogenetics
Cytogenetic studies have revealed a frequent inactivation of CDKN2B (p15(INK4b)) and CDKN2A (p16(INK4a)) as a result of promoter hypermethylation (respectively, 11% and 44% of all PCDLBCLs) and chromosomal imbalances in up to 85% of PCDLBCL, leg type (mainly gains of chromosome 2q, 3, 7p, 12q, 18q and losses of 6q, 13,14,17p, 19) . Translocations of MYC, BCL6, and IGH genes have been demonstrated by fluorescence in situ hybridization in PCDLBCL, leg type. PCLBCL leg type exhibits a unique mutational landscape, combining highly recurrent hotspot mutations in genes involved in NF-kb and B-cell signaling pathways, which provides a rationale for using selective inhibitors of the B-cell receptor (Swerdlow, et al, 2008 . Selva, et al, 2017 . Mareschal, et al. 2017 .
